A new line of products called equivalars aim to displace popular and expensive treatment patents available today.
A new company formed to develop drugs aims to tackle expensive name brand treatments available today and fight extreme over-pricing in the industry. EQRx plans to redesign the development process and generate ten new approved medicines by 2030.